We are happy to share that the Durbin amendment passed by a vote of 66-32 on June 7th, this would not have been possible without so many advocates’ efforts!
The passage of this amendment preserves federal funding of biomedical research – including breast cancer research – conducted through the Department of Defense (DOD).
The bipartisan amendment, led by Sen. Richard Durbin (D-Ill) and Sen. Thad Cochran (R-Miss), passed the
Senate on a 66-32. Its passage blocked an effort that would have prohibited biomedical research funding at the DOD unless the research met narrowly defined criteria related to military relevance. This included funding for the DOD’s Breast Cancer Research Program.
“Passage of this amendment today ensures that critical, innovative cancer research will continue,” said Dr. Judy Salerno, president and CEO of Susan G. Komen. “We are extremely grateful to Senators Durbin and Cochran, and to those senators who voted for its passage. Investment in biomedical research must remain an unwavering national priority if we hope to continue the progress we are making to find the cures.”
Since its inception in 1992, the Breast Cancer Research Program at the DOD has awarded more than $3.2 billion to more than 6,500 research grants aimed at identifying how and why breast cancer develops, factors that increase risk, and more advanced ways to detect and treat the disease.